Candel Therapeutics

CADL

Market cap $281M

NEEDHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on February 28, 2026, the Compensation Committee of Candel's Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 20,000 shares of the Company's common stock, with a per share exercise price of $5.25.

NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will present at TD Cowen's 46th Annual Health Care Conference, being held on March 2-4, 2026 in Boston, MA.

Candel Therapeutics Inc (NASDAQ:CADL) told investors on Thursday it has priced its previously disclosed public offering of about 18.3 million shares at $5.45 per share. The clinical-stage biopharmaceutical company said the offering is expected to generate gross proceeds of about $100 million, before deducting underwriting discounts, commissions and other expenses.

U.S. stock futures rose on Friday after closing lower on Thursday. Futures of all the major benchmark indices were positive.

NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the pricing of an underwritten public offering of 18,348,624 shares of its common stock at a price to the public of $5.45 per share.

Candel Therapeutics Inc (NASDAQ:CADL) on Thursday announced two financing initiatives to support the potential US launch of its cancer therapy aglatimagene besadenovec (CAN-2409) for intermediate- to high-risk localized prostate cancer: a $100 million royalty funding agreement with RTW Investments and a proposed $100 million public offering of common stock. The royalty funding agreement provides Candel with non-dilutive financing to strengthen its balance sheet for a potential commercial launch of aglatimagene in the United States, subject to US Food and Drug Administration (FDA) approval.

NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the launch of an underwritten public offering of $100 million of its common stock.

NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced a $100 million royalty funding agreement with funds managed by RTW Investments, LP (RTW), subject to FDA approval of aglatimagene in intermediate- to high-risk, localized prostate cancer.

NEEDHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that Francesca Barone, M.D., Ph.D., Candel's Chief Scientific Officer, will present data and participate in multiple sessions at the 7th Annual Glioblastoma Drug Development Summit, taking place February 17-19, 2026 in Boston, Massachusetts.

NEEDHAM, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on January 31, 2026, the Compensation Committee of Candel's Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 6,600 shares of the Company's common stock, with a per share exercise price of $5.84.